Chesapeake Wealth Management Sells 107 Shares of Eli Lilly and Company (NYSE:LLY)

Chesapeake Wealth Management trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 3,430 shares of the company’s stock after selling 107 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of Chesapeake Wealth Management’s portfolio, making the stock its 27th largest position. Chesapeake Wealth Management’s holdings in Eli Lilly and Company were worth $3,039,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Knuff & Co LLC grew its holdings in Eli Lilly and Company by 12.8% in the 3rd quarter. Knuff & Co LLC now owns 1,038 shares of the company’s stock worth $920,000 after acquiring an additional 118 shares during the last quarter. Caprock Group LLC grew its stake in shares of Eli Lilly and Company by 13.5% in the third quarter. Caprock Group LLC now owns 67,759 shares of the company’s stock worth $60,031,000 after purchasing an additional 8,051 shares during the last quarter. Aviance Capital Partners LLC grew its stake in shares of Eli Lilly and Company by 63.0% in the third quarter. Aviance Capital Partners LLC now owns 6,919 shares of the company’s stock worth $6,130,000 after purchasing an additional 2,675 shares during the last quarter. Baron Wealth Management LLC raised its position in Eli Lilly and Company by 31.9% during the 3rd quarter. Baron Wealth Management LLC now owns 550 shares of the company’s stock valued at $487,000 after purchasing an additional 133 shares during the last quarter. Finally, OneAscent Wealth Management LLC bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $400,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Bank of America lowered their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Truist Financial upped their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $727.57 on Tuesday. The firm has a market cap of $690.70 billion, a PE ratio of 78.66, a PEG ratio of 2.82 and a beta of 0.43. The stock has a 50 day moving average of $879.04 and a 200 day moving average of $870.84. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same period last year, the company earned $0.10 earnings per share. The firm’s revenue was up 20.4% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.